{
  "meta": {
    "title": "12_Leukemia",
    "url": "https://brainandscalpel.vercel.app/12-leukemia-7561cfbb.html",
    "scrapedAt": "2025-11-30T06:59:14.083Z"
  },
  "questions": [
    {
      "id": 51380,
      "choices": [
        {
          "id": 221667,
          "text": "Blood haemoglobin"
        },
        {
          "id": 221668,
          "text": "Peripheral smear"
        },
        {
          "id": 221669,
          "text": "Platelets"
        },
        {
          "id": 221670,
          "text": "Bone marrow (reticulin)"
        }
      ],
      "text": "A patient presented with painless b/I proptosis. What is the next investigation to diagnose it as chloroma?",
      "unique_key": "Q7883441",
      "question_audio": null,
      "question_video": null,
      "map_id": 34327618,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Peripheral smear Chloroma or myeloblastoma or granulocytic sarcoma is extramedullary blast proliferation which may coexist with acute myeloid leukemia and hence a primary first line investigation of the peripheral blood is needed. Option A- Establishing anemia will not contribute to diagnosis Option C- No history of bleeding- hence not needed here Option D- to determine fibrosis in marrow- not needed here",
      "correct_choice_id": 221668,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78302451700645527/78302451700645527.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78302451700645527/78302451700645527.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51381,
      "choices": [
        {
          "id": 221671,
          "text": "Age > 10 years"
        },
        {
          "id": 221672,
          "text": "Hyperdiploidy"
        },
        {
          "id": 221673,
          "text": "T cell variant"
        },
        {
          "id": 221674,
          "text": "TLC > 1,00,000/ul"
        }
      ],
      "text": "Good prognosis for ALL is?",
      "unique_key": "Q9545480",
      "question_audio": null,
      "question_video": null,
      "map_id": 34631075,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Hyperdiploidy Hyperdiploidy, which refers to the presence of more than the normal number of chromosomes (typically >50 chromosomes), is associated with a good prognosis in acute lymphoblastic leukemia (ALL), particularly in children. This genetic feature is linked to favorable outcomes, as hyperdiploidy is often seen in patients with a better response to treatment and higher survival rates. It is considered a positive prognostic indicator in ALL, especially when compared to other chromosomal abnormalities. Incorrect Responses: A. Age > 10 years: Older age, specifically over 10 years, is generally considered a poor prognostic factor in ALL. Children aged 1 to 10 years tend to have a better prognosis compared to those above 10 years. The prognosis worsens with increasing age, partly due to the biology of the disease being different in older children and adults. C. T cell variant: The T-cell variant of ALL typically carries a poorer prognosis compared to B-cell precursor ALL. T-cell ALL is often more aggressive, harder to treat, and has lower survival rates. It is associated with a higher likelihood of relapse and a more challenging treatment response. D. TLC > 1,00,000/µL: A total leukocyte count (TLC) greater than 100,000/µL (hyperleukocytosis) is associated with a worse prognosis in ALL. Extremely high white blood cell counts can indicate a more aggressive form of leukemia and increase the risk of complications such as leukostasis (clogging of small blood vessels by leukemic cells), which can worsen the clinical outcome.",
      "correct_choice_id": 221672,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32593151700645554/32593151700645554.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/32593151700645554/32593151700645554.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51382,
      "choices": [
        {
          "id": 221675,
          "text": "t(8:14)"
        },
        {
          "id": 221676,
          "text": "t(15:17)"
        },
        {
          "id": 221677,
          "text": "t(9:22)"
        },
        {
          "id": 221678,
          "text": "t(8:11)"
        }
      ],
      "text": "Most common translocation in acute promyelocytic leukemia? (PGI)",
      "unique_key": "Q4377342",
      "question_audio": null,
      "question_video": null,
      "map_id": 34465163,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) t(15;17). This is because the t(15;17) translocation is the most common and characteristic genetic abnormality in acute promyelocytic leukemia (APL). It involves the fusion of the PML (promyelocytic leukemia) gene on chromosome 15 and the RARA (retinoic acid receptor alpha) gene on chromosome 17. This fusion creates the PML-RARA fusion protein, which is an abnormal protein that blocks the normal maturation and differentiation of myeloid cells, leading to the accumulation of immature promyelocytes in the bone marrow and blood, which is the defining feature of APL. The identification of this specific translocation is crucial for diagnosis and for guiding treatment, as APL is uniquely responsive to therapies like all-trans retinoic acid (ATRA) and arsenic trioxide that target the abnormal PML-RARA protein.",
      "correct_choice_id": 221676,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15242621700645567/15242621700645567.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15242621700645567/15242621700645567.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51383,
      "choices": [
        {
          "id": 221679,
          "text": "Hyperploidy"
        },
        {
          "id": 221680,
          "text": "Organomegaly"
        },
        {
          "id": 221681,
          "text": "TLC more than 50,000/ul"
        },
        {
          "id": 221682,
          "text": "Response to treatment"
        }
      ],
      "text": "Which one is the best prognostic factor for ALL?",
      "unique_key": "Q6210855",
      "question_audio": null,
      "question_video": null,
      "map_id": 34951173,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Response to treatment The best prognostic factor for Acute Lymphoblastic Leukemia (ALL) is the patient's response to treatment, particularly early during induction therapy. A rapid and complete response to chemotherapy, often assessed by minimal residual disease (MRD) testing, strongly correlates with better outcomes and higher survival rates. Patients who achieve a complete remission quickly are more likely to have long-term survival and lower relapse rates. Therefore, the response to treatment is considered the most reliable predictor of prognosis in ALL. Incorrect Responses: A. Hyperploidy: While hyperploidy (increased chromosome number) is generally a favorable prognostic factor in childhood ALL, it is not the most important factor when compared to the response to treatment. Hyperploidy is associated with a better outcome, but it alone cannot predict survival as accurately as early treatment response. B. Organomegaly: The presence of organomegaly (enlarged liver, spleen, or lymph nodes) at diagnosis can sometimes indicate a more advanced or aggressive form of ALL. However, organomegaly alone does not have the same prognostic significance as the patient's early response to treatment, which is a stronger predictor of long-term survival. C. TLC more than 50,000/µL: A total leukocyte count (TLC) greater than 50,000/µL can be associated with a worse prognosis, as high white blood cell counts at diagnosis are often seen in more aggressive forms of ALL. However, this is not the best prognostic factor. Early treatment response is a more reliable predictor of outcome than initial TLC values.",
      "correct_choice_id": 221682,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39067451700645585/39067451700645585.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39067451700645585/39067451700645585.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51384,
      "choices": [
        {
          "id": 221683,
          "text": "Myeloperoxidase"
        },
        {
          "id": 221684,
          "text": "Leukocyte alkaline phosphatase"
        },
        {
          "id": 221685,
          "text": "Nonspecific esterase"
        },
        {
          "id": 221686,
          "text": "Neuron specific enolase"
        }
      ],
      "text": "Stain used for diagnosis of granulocytic sarcoma:",
      "unique_key": "Q9896702",
      "question_audio": null,
      "question_video": null,
      "map_id": 34222220,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Myeloperoxidase The MPO reaction is positive in cells of the granulocytic series and may be positive in monocytes. The basis of the stain is breakdown of hydrogen peroxide by the enzyme MPO, releasing an oxygen radical that reacts with a soluble substrate (e.g.,diaminobenzidine or o-tolidine) to form a colored precipitate. MPO is located in the peroxisomes of neutrophils and monocytes and specific granules of eosinophils. Lymphoid cells and erythroid precursors are negative. SBB is a direct stain of phospholipid in granule membranes. The pattern of staining closely parallels that of MPO, but the SBB reaction is usually stronger. Monoblasts may contain sudanophilic granules. Erythroid precursors are negative. Auer rods are MPO- and SBB-positive. Nonspecific esterase reactivity is found in monocytes. The basis for the esterase cytochemical stains is enzymatic release of a side chain from a naphthol ring, with subsequent reaction of the free ring with a soluble color developer to generate a colored precipitate. The most commonly used substrates for NSE are α-naphthyl butyrate (ANB) and α-naphthyl acetate (ANA). Megakaryoblasts are negative with ANB staining. These features may be used to identify megakaryoblasts The PAS stain reacts primarily with glycogen, generating a fuchsia-colored precipitate. Lymphoblasts in ALL often have prominent coarse granular or block PAS staining, but the stain is of limited utility for leukemia diagnosis, as it is not specific for lymphoblasts. AML-M6 will have circumferential PAS staining positivity",
      "correct_choice_id": 221683,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7298701700645597/7298701700645597.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7298701700645597/7298701700645597.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51385,
      "choices": [
        {
          "id": 221687,
          "text": "M2"
        },
        {
          "id": 221688,
          "text": "M3"
        },
        {
          "id": 221689,
          "text": "M6"
        },
        {
          "id": 221690,
          "text": "M7"
        }
      ],
      "text": "Most common type of AML in Down’s syndrome:",
      "unique_key": "Q5264509",
      "question_audio": null,
      "question_video": null,
      "map_id": 34019578,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) M7 The most common type of acute myeloid leukemia (AML) seen in individuals with Down syndrome is M7, which is megakaryoblastic leukemia. Down syndrome (trisomy 21) is associated with an increased risk of developing AML, particularly M7, due to the genetic abnormalities that affect megakaryocyte and platelet development. This form of leukemia typically presents in young children with Down syndrome and is characterized by the proliferation of immature megakaryocytes in the bone marrow. Incorrect Responses: A. M2: M2 is the classification of AML with maturation, where there is both blast cell proliferation and maturation of myeloid cells. While M2 is a common type of AML in the general population, it is not the most common in individuals with Down syndrome. B. M3: M3, also known as acute promyelocytic leukemia (APL), is characterized by the accumulation of abnormal promyelocytes. While APL is associated with a specific genetic abnormality (the t(15;17) translocation), it is not the most common type of AML seen in Down syndrome. C. M6: M6 refers to erythroleukemia, a rare form of AML characterized by the presence of both erythroid and myeloid cells in the marrow. It is not the most common type of AML in Down syndrome. M7 is far more prevalent in this population.",
      "correct_choice_id": 221690,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34757251700645630/34757251700645630.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34757251700645630/34757251700645630.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51386,
      "choices": [
        {
          "id": 221691,
          "text": "Myeloblastic leukemia without maturation"
        },
        {
          "id": 221692,
          "text": "Myeloblastic leukemia with maturation"
        },
        {
          "id": 221693,
          "text": "Promyelocytic leukemia"
        },
        {
          "id": 221694,
          "text": "Myelomonocytic leukemia"
        }
      ],
      "text": "A 15-years-old boy presented with one day history of bleeding gums, sub-conjunctival bleed and purpuric rash. Investigations revealed the fol- lowing results: Hb-6.4 gm/dL; TLC- 26,500/mm3, Platelet 35,000/mm3; prothrombin time-20 sec with a con- trol of 13 sec; partial thromboplastin time-50 sec; and Fibrinogen 10mg/ dL. Peripheral smear was sugges- tive of Acute Myeloblastic Leukemia. Which of the following is the most likely-",
      "unique_key": "Q1789023",
      "question_audio": null,
      "question_video": null,
      "map_id": 34094224,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Promyelocytic leukemia The most likely diagnosis for this 15-year-old boy, who presents with symptoms such as bleeding gums, sub-conjunctival bleeding, purpuric rash, and laboratory findings suggestive of acute myeloblastic leukemia (AML), is acute promyelocytic leukemia (APL), which is a subtype of AML. APL is characterized by the accumulation of abnormal promyelocytes in the bone marrow and blood. It is particularly associated with a coagulopathy, leading to bleeding manifestations, which this patient is exhibiting. The prolonged prothrombin time (PT) and partial thromboplastin time (PTT), along with the very low fibrinogen levels, are consistent with the consumptive coagulopathy seen in APL. This coagulopathy occurs due to the release of tissue factor from promyelocytes, which triggers widespread clotting and consumption of clotting factors, including fibrinogen. Incorrect Responses: A. Myeloblastic leukemia without maturation: This refers to a type of AML where the blasts do not show significant maturation. It is unlikely to cause the severe coagulopathy observed in this case. The presence of bleeding symptoms and abnormal coagulation findings makes APL a more likely diagnosis. B. Myeloblastic leukemia with maturation: This subtype of AML involves the maturation of myeloid cells beyond the blast stage. However, it is not associated with the distinctive coagulopathy seen in APL, which is a hallmark of the disease, making this diagnosis less likely. D. Myelomonocytic leukemia: This is another subtype of AML, characterized by the presence of both myeloid and monocytic differentiation. It does not typically present with the severe bleeding and coagulopathy observed in this patient, making it a less likely diagnosis compared to APL.",
      "correct_choice_id": 221693,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5120511700645660/5120511700645660.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5120511700645660/5120511700645660.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51387,
      "choices": [
        {
          "id": 221695,
          "text": "Polycythemia"
        },
        {
          "id": 221696,
          "text": "Thrombocytosis"
        },
        {
          "id": 221697,
          "text": "Basophilia"
        },
        {
          "id": 221698,
          "text": "Lymphocytosis"
        }
      ],
      "text": "Flow cytometry is done on:",
      "unique_key": "Q1972805",
      "question_audio": null,
      "question_video": null,
      "map_id": 34640186,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Lymphocytosis Flow cytometry is a powerful technique used to analyze and quantify specific cell populations based on their surface markers, and it is particularly useful for diagnosing and monitoring various hematological conditions. In the context of lymphocytosis (an elevated number of lymphocytes in the blood), flow cytometry is commonly used to assess the subtypes of lymphocytes (e.g., T cells, B cells, NK cells) and to determine whether there is any clonal expansion, which is seen in conditions such as chronic lymphocytic leukemia (CLL) or lymphomas. This helps in diagnosing lymphoproliferative disorders and distinguishing between benign and malignant causes of lymphocytosis. Incorrect Responses: A. Polycythemia: Polycythemia, which involves an increase in red blood cells, is typically diagnosed through blood tests such as hemoglobin/hematocrit levels, erythropoietin levels, and genetic tests (e.g., JAK2 mutations), rather than flow cytometry. Flow cytometry is not routinely used for diagnosing polycythemia. B. Thrombocytosis: Thrombocytosis refers to an elevated platelet count. While flow cytometry can be used to analyze platelets in certain cases, it is not the primary diagnostic tool for thrombocytosis. Thrombocytosis is usually evaluated through a complete blood count (CBC) and peripheral blood smear. C. Basophilia: Basophilia, which is an increase in basophils in the blood, is generally diagnosed using a peripheral blood smear and CBC. Flow cytometry is not typically used for the routine evaluation of basophils unless there is a need to investigate a specific underlying condition, such as chronic myelogenous leukemia (CML), where flow cytometry might be used for more detailed analysis.",
      "correct_choice_id": 221698,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29469791700645724/29469791700645724.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29469791700645724/29469791700645724.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51388,
      "choices": [
        {
          "id": 221699,
          "text": "Mature B cell"
        },
        {
          "id": 221700,
          "text": "Naïve B cell"
        },
        {
          "id": 221701,
          "text": "Centrocytes of germinal center"
        },
        {
          "id": 221702,
          "text": "Progenitor B-cell"
        }
      ],
      "text": "CLL/SLL ARISES FROM WHICH CELL?",
      "unique_key": "Q3468884",
      "question_audio": null,
      "question_video": null,
      "map_id": 34068574,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Naïve B cell Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) both arise from naïve B cells. These are mature B cells that have not yet encountered their specific antigen and have not gone through the process of activation or differentiation in the germinal centers. In CLL/SLL, these naïve B cells acquire genetic mutations, leading to their uncontrolled proliferation and accumulation in the blood (CLL) or lymphoid tissues (SLL). Incorrect Responses: A. Mature B cell: While CLL/SLL involves mature B cells, it specifically arises from naïve B cells, which are a subset of mature B cells that have not yet been activated by an antigen. Mature B cells have undergone class-switching and affinity maturation, and they are not the origin of CLL/SLL. C. Centrocytes of germinal center: Centrocytes are differentiated B cells from the germinal center that have undergone class switching and somatic hypermutation. CLL/SLL does not arise from these cells. Germinal center B cells are more involved in the pathogenesis of other B-cell lymphomas like follicular lymphoma. D. Progenitor B-cell: Progenitor B-cells are early precursors in the B-cell development process, and CLL/SLL does not arise from this stage. CLL/SLL specifically originates from mature naïve B-cells, which are further along in the differentiation process than progenitor B-cells.",
      "correct_choice_id": 221700,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35263931700645743/35263931700645743.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35263931700645743/35263931700645743.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51389,
      "choices": [
        {
          "id": 221703,
          "text": "SOX11"
        },
        {
          "id": 221704,
          "text": "ITRA1"
        },
        {
          "id": 221705,
          "text": "MYD88"
        },
        {
          "id": 221706,
          "text": "Annexin V"
        }
      ],
      "text": "Which of the following immunohisto chemistry marker is used in Cyclin D1 negative Mantle cell lymphoma?",
      "unique_key": "Q9734983",
      "question_audio": null,
      "question_video": null,
      "map_id": 34073602,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) SOX11 In cases of Cyclin D1-negative Mantle Cell Lymphoma (MCL), SOX11 is a useful immunohistochemistry marker. Mantle cell lymphoma typically shows Cyclin D1 positivity, but in some cases, such as those that are Cyclin D1-negative, SOX11 can be used as a reliable marker for diagnosis. SOX11 is a transcription factor that is expressed in a significant proportion of mantle cell lymphomas, especially those that are negative for Cyclin D1. Incorrect Responses: B. ITRA1: ITRA1 is a marker associated with certain types of T-cell lymphomas, but it is not used for diagnosing mantle cell lymphoma, particularly in the context of Cyclin D1 negativity. It is not specific to mantle cell lymphoma. C. MYD88: MYD88 is a marker associated with Waldenström's macroglobulinemia and some other B-cell lymphomas, but it is not typically used to diagnose mantle cell lymphoma, particularly when Cyclin D1 is negative. MYD88 mutations are more relevant in Lymphoplasmacytic lymphoma. D. Annexin V: Annexin V is a marker for apoptosis and is not used for the diagnosis of mantle cell lymphoma. It detects phosphatidylserine exposure on the surface of cells during apoptosis, but it is not relevant for identifying Cyclin D1-negative mantle cell lymphoma.",
      "correct_choice_id": 221703,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24632731700645757/24632731700645757.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24632731700645757/24632731700645757.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51390,
      "choices": [
        {
          "id": 221707,
          "text": "Bone marrow with reticulin stain"
        },
        {
          "id": 221708,
          "text": "JAK STAT mutation assessment"
        },
        {
          "id": 221709,
          "text": "Philadelphia chromosome"
        },
        {
          "id": 221710,
          "text": "Erythropoietin levels"
        }
      ],
      "text": "A 60-years-old male living in hilly area has Hb of 16 gm%, TC 21000/ ul. DLC showed metamyelocytes and myelocytes 40%, N25% L40%, E5%. Platelet count 3.25 lakh/u. He presented with hypertension and on examination, spleen was just palpable below costal margin. What is the next step?",
      "unique_key": "Q9054124",
      "question_audio": null,
      "question_video": null,
      "map_id": 34667651,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Erythropoietin levels The patient's clinical presentation, including spleen enlargement, elevated hemoglobin (Hb), and leukocytosis (with myelocytes and metamyelocytes), is suggestive of a myeloproliferative disorder. Given his high hemoglobin and the absence of features typical of chronic myelogenous leukemia (Philadelphia chromosome positivity), the most likely diagnosis is polycythemia vera (PV). In polycythemia vera, there is an overproduction of red blood cells, white blood cells, and platelets, which is often driven by a mutation in the JAK2 gene, specifically JAK2 V617F. The next step in this case would be to measure erythropoietin (EPO) levels, as low EPO levels are characteristic of polycythemia vera (since the body’s feedback mechanism is impaired and does not produce enough EPO despite high red cell production). This would help differentiate polycythemia vera from secondary polycythemia, which is usually caused by high EPO levels due to chronic hypoxia or tumors producing erythropoietin (e.g., renal cell carcinoma). Incorrect Responses: A. Bone marrow with reticulin stain: A bone marrow biopsy can be helpful in diagnosing myeloproliferative disorders like polycythemia vera, but the most immediate and useful test is assessing erythropoietin (EPO) levels to confirm or rule out polycythemia vera before proceeding to a bone marrow examination. B. JAK STAT mutation assessment: While JAK2 mutations (especially JAK2 V617F) are commonly seen in polycythemia vera, erythropoietin levels are a more immediate and straightforward diagnostic test. JAK2 mutation assessment is an important test but comes after ruling out secondary causes of polycythemia with EPO levels. C. Philadelphia chromosome: The Philadelphia chromosome is a diagnostic feature of chronic myelogenous leukemia (CML), and although this patient has elevated WBC count and some myeloid features (e.g., metamyelocytes, myelocytes), the absence of basophilia and elevated eosinophils, along with the normal platelet count and absence of splenomegaly, makes CML less likely. Therefore, this test is not appropriate at this stage.",
      "correct_choice_id": 221710,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28945341700645880/28945341700645880.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28945341700645880/28945341700645880.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51391,
      "choices": [
        {
          "id": 221711,
          "text": "t(1;21)"
        },
        {
          "id": 221712,
          "text": "t(9;22)"
        },
        {
          "id": 221713,
          "text": "t(15;17)"
        },
        {
          "id": 221714,
          "text": "Trisomy 21"
        }
      ],
      "text": "A 60-years-old man presented with fatigue, weight loss and heaviness in left hypochondrium for 6 months. The hemo-gram showed Hb=10 gm/ dL, TLC 5 lakhs/mm3, platelet count 4 lakhs/mm3, DLC neutrophil 55% lymphocytes 4% monocytes 2?sophils 6% metamyelocytes 10%, myelocytes 18%, promyelocytes 2% and blasts 3%. The most likely cytogenetic abnormality in this case is:",
      "unique_key": "Q9477347",
      "question_audio": null,
      "question_video": null,
      "map_id": 34021740,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) t(9;22) The patient's presentation with fatigue, weight loss, and heaviness in the left hypochondrium suggests a possible leukemia. The hemogram showing a markedly elevated total leukocyte count (TLC) of 5 lakh/mm3, along with the presence of blasts, myelocytes, and metamyelocytes in the differential count, is highly indicative of Chronic Myelogenous Leukemia (CML), particularly in the blast crisis phase. The t(9;22) chromosomal translocation, known as the Philadelphia chromosome, is a hallmark of CML. This translocation leads to the formation of the BCR-ABL fusion gene, which produces a constitutively active tyrosine kinase that drives uncontrolled proliferation of myeloid cells, resulting in the characteristic leukocytosis and the presence of immature cells in the peripheral blood. Incorrect Responses: A. t(1;21): The t(1;21) translocation is not commonly associated with leukemia. It is more often observed in some myeloproliferative disorders but not in CML. This translocation is rarely found in hematological malignancies and is not linked with the findings in this patient. C. t(15;17): The t(15;17) translocation is characteristic of Acute Promyelocytic Leukemia (APL), a subtype of Acute Myelogenous Leukemia (AML). It results in the PML-RAR? fusion gene. However, the patient's presentation with chronic leukocytosis and blasts more strongly suggests CML rather than APL, which usually presents acutely. D. Trisomy 21: Trisomy 21, also known as Down syndrome, is associated with an increased risk of acute leukemias, particularly acute lymphoblastic leukemia (ALL) and AML in childhood. However, this cytogenetic abnormality is not directly linked to CML, and the patient's presentation is more consistent with CML rather than leukemia associated with Down syndrome.",
      "correct_choice_id": 221712,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56696101700645926/56696101700645926.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56696101700645926/56696101700645926.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51392,
      "choices": [
        {
          "id": 221715,
          "text": "Presence of blasts with deeply basophilic and vacuolated cytoplasm"
        },
        {
          "id": 221716,
          "text": "Presence of Auer rods in the blasts"
        },
        {
          "id": 221717,
          "text": "Presence of small blasts with round nuclei, variably dispersed chromatin, occasional nucleoli and scant amounts of basophilic cytoplasm"
        },
        {
          "id": 221718,
          "text": "Presence of large blasts with round nuclei, dispersed chromatin prominent nucleoli and abundant basophilic cytoplasm"
        }
      ],
      "text": "A 50-years-old man presents with fatigue and easy bruising. A complete blood count and peripheral blood smear show leucocytosis with 56% circulating blasts. The patient has no previous history of myeloid neoplasm or treatment with hemotherapy. Which of the following findings would definitively establish a diagnosis of acute myeloid leukemia?",
      "unique_key": "Q9289120",
      "question_audio": null,
      "question_video": null,
      "map_id": 34827811,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Presence of Auer rods in the blasts The diagnosis of Acute Myeloid Leukemia (AML) is primarily based on the morphological features of blasts in the peripheral blood or bone marrow, along with specific cytogenetic or molecular findings. Auer rods are needle-shaped cytoplasmic inclusions that are considered a hallmark feature of AML, particularly in myeloblasts. The presence of Auer rods indicates that the blasts are of myeloid origin, which is key in confirming the diagnosis of AML. Incorrect Responses: A. Presence of blasts with deeply basophilic and vacuolated cytoplasm: While vacuolation can be seen in various forms of leukemia, including AML, it is not specific or definitive for the diagnosis. Auer rods are a more definitive and specific feature of AML. C. Presence of small blasts with round nuclei, variably dispersed chromatin, occasional nucleoli and scant amounts of basophilic cytoplasm: These features are typical of lymphoblasts, which are seen in acute lymphoblastic leukemia (ALL), not AML. The blast morphology described here is more consistent with ALL rather than AML. D. Presence of large blasts with round nuclei, dispersed chromatin, prominent nucleoli and abundant basophilic cytoplasm: While this description could represent myeloblasts, it is not specific enough to definitively diagnose AML. The presence of Auer rods (as in option B) would be a more specific and diagnostic feature of AML.",
      "correct_choice_id": 221716,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27670981700645950/27670981700645950.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27670981700645950/27670981700645950.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51393,
      "choices": [
        {
          "id": 221719,
          "text": "t(8;21)(q22;q22)"
        },
        {
          "id": 221720,
          "text": "t(9;11)(q22;q23)"
        },
        {
          "id": 221721,
          "text": "t(6;9)(q23;q34)"
        },
        {
          "id": 221722,
          "text": "t(3;3)(q21;q26.2)"
        }
      ],
      "text": "Detection of which of the following molecular genetic abnormalities is equivalent to a diagnosis of acute myeloid leukemia, regardless of blast count?",
      "unique_key": "Q5570912",
      "question_audio": null,
      "question_video": null,
      "map_id": 34770029,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) t(8;21)(q22;q22) The t(8;21)(q22;q22) translocation is one of the most well-established genetic abnormalities in Acute Myeloid Leukemia (AML). This specific chromosomal translocation involves the fusion of the RUNX1 gene on chromosome 21 and the ETO gene on chromosome 8, leading to the production of the RUNX1-ETO fusion protein. The detection of this translocation is considered a diagnostic feature of AML, regardless of the blast count in the peripheral blood or bone marrow. This translocation is a key genetic marker for a subtype of AML that often has a relatively good prognosis. Incorrect Responses: B. t(9;11)(q22;q23): This translocation results in the fusion of the MLL gene (also known as KMT2A) on chromosome 11 and the AF9 gene on chromosome 9. It is a recognized abnormality in AML and other hematologic malignancies, but t(9;11) alone is not enough to diagnose AML independently of blast count. C. t(6;9)(q23;q34): This translocation, which results in the fusion of the DEK gene on chromosome 6 and the CAN gene on chromosome 9, is associated with AML, but it is not sufficient on its own to establish a diagnosis of AML. This abnormality may be present in cases of AML but does not independently confirm the diagnosis in the absence of other features such as blast count. D. t(3;3)(q21;q26.2): This translocation is associated with AML, specifically a subtype that is characterized by poor prognosis. However, like t(9;11) and t(6;9), the presence of this translocation alone does not provide a definitive diagnosis of AML without the appropriate clinical and hematologic findings, including an elevated blast count.",
      "correct_choice_id": 221719,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11830961700645973/11830961700645973.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11830961700645973/11830961700645973.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51394,
      "choices": [
        {
          "id": 221723,
          "text": "t(15;17)"
        },
        {
          "id": 221724,
          "text": "Inv(16)(p13.1q22)"
        },
        {
          "id": 221725,
          "text": "t(6:9)"
        },
        {
          "id": 221726,
          "text": "t(9:22)"
        }
      ],
      "text": "Which of the following molecular genetic abnormalities results in the disruption of core binding factor-?",
      "unique_key": "Q8296313",
      "question_audio": null,
      "question_video": null,
      "map_id": 34875826,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Inv(16)(p13.1q22) The Inv(16)(p13.1q22) chromosomal inversion is a genetic abnormality associated with Acute Myelomonocytic Leukemia (AMML), particularly with the core binding factor (CBF) disruption. This inversion results in the CBF?-MYH11 fusion gene, which disrupts the normal function of the core binding factor (CBF), a critical transcription factor for myeloid cell development. The CBF?-MYH11 fusion gene leads to the disruption of the core binding factor (CBF) pathway, which plays a role in hematopoiesis and the regulation of myeloid differentiation. This abnormality is typically associated with a better prognosis in AML. Incorrect Responses: A. t(15;17): The t(15;17) translocation is characteristic of Acute Promyelocytic Leukemia (APL), not AMML. It results in the PML-RAR? fusion gene, which disrupts the function of the retinoic acid receptor and is associated with differentiation block in promyelocytes. This translocation is not related to the disruption of core binding factor (CBF). C. t(6;9): The t(6;9) translocation involves the DEK and CAN genes and is associated with a specific subtype of AML. It does not result in the disruption of core binding factor (CBF). D. t(9;22): The t(9;22) translocation, or Philadelphia chromosome, is associated with Chronic Myelogenous Leukemia (CML) and some cases of AML. This translocation results in the BCR-ABL fusion gene, which is not related to the disruption of core binding factor (CBF) but instead involves the activation of the tyrosine kinase pathway.",
      "correct_choice_id": 221724,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29979771700645990/29979771700645990.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29979771700645990/29979771700645990.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51395,
      "choices": [
        {
          "id": 221727,
          "text": "The disease shows a poor response to treatment"
        },
        {
          "id": 221728,
          "text": "The disease is almost always preceded by chronic myelogenous leukemia"
        },
        {
          "id": 221729,
          "text": "Patients are at high risk for the development of disseminated intravascular coagulation"
        },
        {
          "id": 221730,
          "text": "Most patients present in the seventh or eight decade of life"
        }
      ],
      "text": "Which of the following statements regarding acute promyelocytic leukemia with PML-RARA is the most correct?",
      "unique_key": "Q8914883",
      "question_audio": null,
      "question_video": null,
      "map_id": 34421348,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Patients are at high risk for the development of disseminated intravascular coagulation (DIC) Acute Promyelocytic Leukemia (APL) with the PML-RARA fusion gene is associated with prominent coagulopathy, particularly disseminated intravascular coagulation (DIC). The presence of DIC is a hallmark feature of APL and is a major cause of morbidity and mortality in affected patients. The PML-RARA fusion gene, resulting from the t(15;17) translocation, disrupts the normal differentiation of promyelocytes, leading to the accumulation of abnormal promyelocytes in the bone marrow. These cells contain granules that release tissue factor, a potent activator of coagulation, contributing to the development of DIC. Incorrect Responses: A. The disease shows a poor response to treatment: This statement is incorrect. APL, specifically the subtype with the PML-RARA fusion gene, is actually highly responsive to treatment, particularly with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). These agents induce differentiation of the abnormal promyelocytes and are associated with high remission rates and cure rates. B. The disease is almost always preceded by chronic myelogenous leukemia: This is incorrect. APL is a distinct subtype of acute myeloid leukemia (AML) and is not typically preceded by chronic myelogenous leukemia (CML). While both diseases involve the myeloid lineage, APL arises de novo due to the t(15;17) translocation and does not usually follow a chronic phase as seen in CML. D. Most patients present in the seventh or eighth decade of life: This is incorrect. APL typically affects younger patients, usually presenting in the third or fourth decade of life. It is rare in patients older than 70 years, and its occurrence is more common in adults under 40 years.",
      "correct_choice_id": 221729,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24338521700646004/24338521700646004.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24338521700646004/24338521700646004.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51396,
      "choices": [
        {
          "id": 221731,
          "text": "Expression of CD14"
        },
        {
          "id": 221732,
          "text": "Expression of CD34"
        },
        {
          "id": 221733,
          "text": "Expression of CD64"
        },
        {
          "id": 221734,
          "text": "Expression of CD4"
        }
      ],
      "text": "Which of the following findings would not be expected in the blast population of acute myeloid leukemia with monocytic differentiation?",
      "unique_key": "Q9758804",
      "question_audio": null,
      "question_video": null,
      "map_id": 34548436,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Expression of CD4 In acute myeloid leukemia (AML) with monocytic differentiation, the blast population typically exhibits markers associated with the monocytic lineage. These include markers such as CD14, CD64, and CD34 (which is a general marker for hematopoietic stem/progenitor cells, and can be expressed in AML blasts). However, CD4 is typically associated with T cells and not with monocytic differentiation. Therefore, the presence of CD4 would not be expected in the blast population of AML with monocytic differentiation. Incorrect Responses: A. Expression of CD14: CD14 is a marker of monocytic differentiation and is commonly expressed in the blasts of AML with monocytic differentiation. It is a reliable marker for identifying monocytes and macrophages in leukemia. B. Expression of CD34: CD34 is a marker of hematopoietic stem/progenitor cells, and it is often expressed in AML blasts, including those with monocytic differentiation. It can be used to identify the immature state of the blasts. C. Expression of CD64: CD64 is another marker of monocytic differentiation and is typically expressed on monocytes and macrophages. It is commonly seen in the blast population of AML with monocytic differentiation.",
      "correct_choice_id": 221734,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3227641700646023/3227641700646023.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3227641700646023/3227641700646023.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51397,
      "choices": [
        {
          "id": 221735,
          "text": "Myelodysplastic syndrome with excess blasts-1"
        },
        {
          "id": 221736,
          "text": "Myelodysplastic syndrome with excess blasts-2"
        },
        {
          "id": 221737,
          "text": "Myelodysplastic syndrome with multilineage dysplasia"
        },
        {
          "id": 221738,
          "text": "Acute myeloid leukemia with myelodysplasia-related changes"
        }
      ],
      "text": "A 70-years-old man presents with pancytopenia for six months. A bonemarrow is performed and shows dys plasia in the granulocyte, erythrocyte and megakaryocyte lineages. The blast count in the peripheral blood is less than 1% and the blast count in the bone marrow is less than 5%. The best diagnosis is:",
      "unique_key": "Q2797381",
      "question_audio": null,
      "question_video": null,
      "map_id": 34062766,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Myelodysplastic syndrome with multilineage dysplasia The presentation of pancytopenia (decreased levels of all blood cell types), along with the findings of dysplasia in the granulocyte, erythrocyte, and megakaryocyte lineages in the bone marrow, is characteristic of Myelodysplastic Syndrome (MDS). The absence of significant blasts (less than 1% in the peripheral blood and less than 5% in the bone marrow) suggests that the disorder is not progressing into acute myeloid leukemia (AML). The term \"multilineage dysplasia\" refers to the abnormal development of all three major hematopoietic lineages (granulocytes, erythrocytes, and megakaryocytes), which is seen in this case. This is a hallmark feature of MDS, and the classification into MDS with multilineage dysplasia is given when there is dysplasia in at least two of the major cell lineages in the bone marrow. Incorrect Responses: A. Myelodysplastic syndrome with excess blasts-1: This classification applies when there is 5-9% blasts in the bone marrow. Since the blast count in the bone marrow is less than 5%, this diagnosis is not appropriate in this case. B. Myelodysplastic syndrome with excess blasts-2: This classification applies when there is 10-19% blasts in the bone marrow. Since the blast count is again less than 5%, this diagnosis is also not appropriate. D. Acute myeloid leukemia with myelodysplasia-related changes: This diagnosis would be considered if the blast count in the bone marrow were 20% or more. In this case, the blast count is less than 5%, ruling out the diagnosis of AML.",
      "correct_choice_id": 221737,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28281221700646037/28281221700646037.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28281221700646037/28281221700646037.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51398,
      "choices": [
        {
          "id": 221739,
          "text": "t (8;14)"
        },
        {
          "id": 221740,
          "text": "t (14:18)"
        },
        {
          "id": 221741,
          "text": "t (15;17)"
        },
        {
          "id": 221742,
          "text": "t (11;14)"
        }
      ],
      "text": "Follicular lymphoma is characterized by the following cytogenetic abnormality:",
      "unique_key": "Q5570818",
      "question_audio": null,
      "question_video": null,
      "map_id": 34515121,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) t(14;18) Follicular lymphoma (FL) is typically characterized by the t(14;18) translocation. This chromosomal abnormality results in the BCL2 gene being translocated from chromosome 18 to chromosome 14, placing it under the control of the IGH (Immunoglobulin heavy chain) promoter. This translocation leads to the overexpression of the BCL2 protein, which is an anti-apoptotic protein that helps lymphoma cells evade programmed cell death (apoptosis), contributing to the development and progression of follicular lymphoma. Incorrect Responses: A. t(8;14): This translocation is characteristic of Burkitt lymphoma, not follicular lymphoma. It involves the MYC gene on chromosome 8 being translocated to the IGH locus on chromosome 14. This results in MYC overexpression, which drives uncontrolled cell growth in Burkitt lymphoma. C. t(15;17): This translocation is seen in acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). It results in the formation of the PML-RARA fusion gene, which blocks myeloid differentiation and leads to the characteristic features of APL. D. t(11;14): This translocation is characteristic of mantle cell lymphoma, not follicular lymphoma. It leads to the overexpression of the Cyclin D1 gene, which is involved in cell cycle regulation and contributes to lymphoma development by promoting cell cycle progression.",
      "correct_choice_id": 221740,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5424491700646052/5424491700646052.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5424491700646052/5424491700646052.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51399,
      "choices": [
        {
          "id": 221743,
          "text": "Effacement of lymph node architecture with presence of large and small cells"
        },
        {
          "id": 221744,
          "text": "Presence of pseudofollicles"
        },
        {
          "id": 221745,
          "text": "Marked increase in vascularity"
        },
        {
          "id": 221746,
          "text": "Large cells resembling Reed- Sternberg cells"
        }
      ],
      "text": "A characteristic feature of lymph node involved by CLL/SLL is:",
      "unique_key": "Q7500875",
      "question_audio": null,
      "question_video": null,
      "map_id": 34265446,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Presence of pseudofollicles Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are closely related diseases, with CLL affecting the peripheral blood and SLL affecting the lymph nodes. A characteristic feature of the lymph nodes involved by CLL/SLL is the presence of pseudofollicles. These pseudofollicles are the result of the infiltration of small B lymphocytes (the characteristic cells of CLL/SLL), often accompanied by proliferating B-cells that mimic the appearance of germinal centers. However, they do not have the typical organization of true follicles, hence the term \"pseudofollicles.\" Incorrect Responses: A. Effacement of lymph node architecture with presence of large and small cells: While CLL/SLL can cause the effacement (loss of normal architecture) of the lymph node, the large cells are typically not the predominant feature. The disease is characterized by small B-cells rather than large cells. The large cells seen in other lymphomas (such as in diffuse large B-cell lymphoma) are not a defining feature of CLL/SLL. C. Marked increase in vascularity: There is typically no marked increase in vascularity in CLL/SLL. In fact, the vascularity in CLL/SLL is generally low compared to more aggressive lymphomas, where vascular changes can be more prominent. D. Large cells resembling Reed-Sternberg cells: Reed-Sternberg cells are characteristic of Hodgkin lymphoma, not CLL/SLL. CLL/SLL is characterized by small, round B-cells, and large cells similar to Reed-Sternberg cells would not be seen.",
      "correct_choice_id": 221744,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69318931700646065/69318931700646065.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69318931700646065/69318931700646065.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51400,
      "choices": [
        {
          "id": 221747,
          "text": "A pseudofollicular pattern with proliferation centers"
        },
        {
          "id": 221748,
          "text": "A monomorphic lymphoid proliferation with a nodular pattern"
        },
        {
          "id": 221749,
          "text": "A predominantly follicular pattern"
        },
        {
          "id": 221750,
          "text": "A diffuse proliferation of medium to large lymphoid cells with high mitotic rate"
        }
      ],
      "text": "A 48-years-old woman was admitted with a history of weakness for two months. On Examination, cervical lymph nodes were found enlarged and spleen was palpable 2 cm below the costal margin. Her haemoglobin was 10.5 g/dL, platelet count 2.7 x 109/L and total leukocyte count 40 x 109/L, which included 80% mature lymphoid cells with coarse clumped chroma tin. Bone marrow revealed a nodular lymphoid infiltrate. The peripheral blood lymphoid cells were positive for CD19, CD5, CD20 and CD23 and were negative for CD79 B and FMC-7. The Histopathological Examination of the lymph node in this patient will most likely exhibit effacement of lymph node architecture by",
      "unique_key": "Q2517467",
      "question_audio": null,
      "question_video": null,
      "map_id": 34047346,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) A pseudofollicular pattern with proliferation centers The patient described presents with cervical lymphadenopathy, splenomegaly, anemia, and a lymphocytosis (80% mature lymphoid cells with coarse clumped chromatin), which suggests a diagnosis of Chronic Lymphocytic Leukemia (CLL). CLL is a B-cell malignancy characterized by mature, small B lymphocytes that infiltrate the bone marrow and lymphoid tissues, leading to a nodular or pseudofollicular pattern on histopathology. In CLL, the lymph nodes typically exhibit effacement of normal architecture with pseudofollicles, which are areas that resemble germinal centers but are not true follicles. The proliferation centers seen in CLL consist of clusters of prolymphocytes or larger malignant cells, which can often be found within the pseudofollicles. Incorrect Responses: B. A monomorphic lymphoid proliferation with a nodular pattern: This description might apply to other lymphomas, but in CLL, the lymph node architecture is typically effaced by pseudofollicles and not a monomorphic nodular pattern. C. A predominantly follicular pattern: This pattern is more typical of follicular lymphoma, where the lymphoma cells resemble the structure of normal germinal centers. CLL, on the other hand, shows a pseudofollicular pattern, not a predominantly follicular one. D. A diffuse proliferation of medium to large lymphoid cells with high mitotic rate: This pattern is more characteristic of aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), which would show larger cells with a high mitotic rate, unlike the small lymphocytes and slower-growing nature of CLL.",
      "correct_choice_id": 221747,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62871871700646148/62871871700646148.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62871871700646148/62871871700646148.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51401,
      "choices": [
        {
          "id": 221751,
          "text": "Monocytic (M5)"
        },
        {
          "id": 221752,
          "text": "Promyelocystic (M3)"
        },
        {
          "id": 221753,
          "text": "Erythroblastic (M6)"
        },
        {
          "id": 221754,
          "text": "Megakaryocytic (M7)"
        }
      ],
      "text": "DIC is common in which AML",
      "unique_key": "Q4011802",
      "question_audio": null,
      "question_video": null,
      "map_id": 34440113,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Promyelocytic (M3) Disseminated intravascular coagulation (DIC) is most commonly associated with acute promyelocytic leukemia (APL), classified as AML-M3. APL is characterized by the translocation t(15;17), which leads to the fusion of the PML gene on chromosome 15 and the RAR-alpha gene on chromosome 17. This results in abnormal promyelocytes that are highly prone to disseminated intravascular coagulation (DIC), a condition where widespread clotting occurs, leading to organ damage and bleeding complications. The presence of Auer rods in promyelocytes and the tendency for bleeding disorders are hallmark features of APL. Incorrect Responses: A. Monocytic (M5): Monocytic AML (M5) is characterized by the proliferation of monocytic cells, but it is not commonly associated with DIC. It typically presents with skin infiltration and can cause gingival hypertrophy, but DIC is not a characteristic feature. C. Erythroblastic (M6): Erythroblastic leukemia (M6) involves the abnormal proliferation of erythroid cells but does not typically lead to DIC. M6 is more likely to present with anemia and splenomegaly, but clotting abnormalities are less frequent. D. Megakaryocytic (M7): Megakaryocytic leukemia (M7) is characterized by the proliferation of megakaryocytes and can be associated with thrombocytosis or thrombocytopenia, but it is not typically associated with DIC.",
      "correct_choice_id": 221752,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76830121700646209/76830121700646209.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76830121700646209/76830121700646209.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51402,
      "choices": [
        {
          "id": 221755,
          "text": "ALL"
        },
        {
          "id": 221756,
          "text": "AML"
        },
        {
          "id": 221757,
          "text": "Undifferentiated leukemia"
        },
        {
          "id": 221758,
          "text": "Mixed phenotypic acute leukemia"
        }
      ],
      "text": "A 10 years old child presents with pallor and history of blood transfusion 2 months back. On investigation, Hb 4.5 gm, total count 60000, platelet count 2 lakh and CD10 (+) ve, CD19 (+) ve, CD117 (+) ve, MPO (+) ve& CD33(-) ve. What is the most likelydiagnosis?",
      "unique_key": "Q3756688",
      "question_audio": null,
      "question_video": null,
      "map_id": 34535271,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Mixed phenotypic acute leukemia Myeloid lineage MPO (by flow cytometry, immunohisto- chemistry, or cytochemistry) or Monocytic differentiation (>2 of the fol- lowing: non-specific esterase, CD11c, CD14, CD64, lysozyme) T-cell lineage Cytoplasmic CD3 (by flow cytometry with antibodies to CD3 epsilon chain. Immunohistochemistry using polyclonal anti-CD3 antibody may detect CD3 zeta chain, which is not T-cell-specific) or Surface CD3 (rare in mixed-phenotype acute leukaemias) B-cell lineage (multiple antigens required) Strong CD19 with > 1 of the following strongly ex- pressed: CD79a, cytoplasmic CD22, CD10 or WeakCD19 with > 2 of the following strongly ex- pressed: CD79a, cytoplasmic CD22, CD10",
      "correct_choice_id": 221758,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65938741700646225/65938741700646225.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65938741700646225/65938741700646225.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51403,
      "choices": [
        {
          "id": 221759,
          "text": "Parvovirus B19"
        },
        {
          "id": 221760,
          "text": "Mycoplasma"
        },
        {
          "id": 221761,
          "text": "Atypical mycobacteria"
        },
        {
          "id": 221762,
          "text": "Salmonella"
        }
      ],
      "text": "Compared to the other leukemias, hairy cell leukemia is associated with which of the following infections",
      "unique_key": "Q7050062",
      "question_audio": null,
      "question_video": null,
      "map_id": 34549551,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Atypical mycobacteria Hairy cell leukemia (HCL) is a rare chronic B-cell leukemia associated with a weakened immune system, specifically causing monocytopenia and functional defects in macrophages. This immunosuppression predisposes patients to infections, particularly by atypical mycobacteria, which are opportunistic pathogens. Examples include Mycobacterium avium complex (MAC) and Mycobacterium kansasii, which commonly affect individuals with compromised immune systems, such as those with HCL. Incorrect Responses: A. Parvovirus B19: This virus is known to cause aplastic crises in individuals with conditions such as sickle cell anemia or other hemolytic anemias. While it may cause cytopenias, it is not typically associated with hairy cell leukemia. B. Mycoplasma: Infections with Mycoplasma pneumoniae are primarily linked to respiratory illnesses, such as atypical pneumonia. They are not a common complication of HCL. D. Salmonella: Salmonella infections are more frequently associated with sickle cell disease due to functional asplenia or other conditions impairing phagocytosis. They are not commonly associated with HCL.",
      "correct_choice_id": 221761,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14420101700646241/14420101700646241.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14420101700646241/14420101700646241.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51404,
      "choices": [
        {
          "id": 221763,
          "text": "Acute lymphoblastic leukemia with aberrant myeloid expression"
        },
        {
          "id": 221764,
          "text": "Acute monoblastic leukemia with aberrant lymphoid expression"
        },
        {
          "id": 221765,
          "text": "Mixed phenotypic acute leukemia"
        },
        {
          "id": 221766,
          "text": "Acute myeloid leukemia"
        }
      ],
      "text": "A patient with increased TLC was investigated for leukemia. On flow cytometry the following profile was obtained. CD 34 positive CD 11c positive CD 14 positive CD 64 positive CD 22 positive CD 19 positive CD 10 positive The diagnosis is?",
      "unique_key": "Q3060384",
      "question_audio": null,
      "question_video": null,
      "map_id": 34377176,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Mixed phenotypic acute leukemia Reference WHO 2017 Myeloid lineage MPO (by flow cytometry, immunohisto- chemistry, or cytochemistry) or Monocytic differentiation (>2 of the fol- lowing: non-specific esterase, CD11c, CD14, CD64, lysozyme) T-cell lineage Cytoplasmic CD3 (by flow cytometry with antibodies to CD3 epsilon chain. Immunohistochemistry using polyclonal anti-CD3 antibody may detect CD3 zeta chain, which is not T-cell-specific) or Surface CD3 (rare in mixed-phenotype acute leukaemias) B-cell lineage (multiple antigens required) Strong CD19 with > 1 of the following strongly ex- pressed: CD79a, cytoplasmic CD22, CD10 or WeakCD19 with >2 of the following strongly ex- pressed: CD79a, cytoplasmic CD22, CD10",
      "correct_choice_id": 221765,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75166861700646328/75166861700646328.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75166861700646328/75166861700646328.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51405,
      "choices": [
        {
          "id": 221767,
          "text": "Expression of CD13 by the blasts"
        },
        {
          "id": 221768,
          "text": "Expression of CD33 by the blasts"
        },
        {
          "id": 221769,
          "text": "Expression of myeloperoxidase by the blasts"
        },
        {
          "id": 221770,
          "text": "Expression of cytoplasmic CD3 by the blasts"
        }
      ],
      "text": "Which of the following findings would be most useful for establishing myeloid lineage in acute leukemia?",
      "unique_key": "Q9171745",
      "question_audio": null,
      "question_video": null,
      "map_id": 34710885,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Expression of myeloperoxidase by the blasts In acute leukemia, the identification of the myeloid lineage of blasts is critical for diagnosis and classification. Myeloperoxidase (MPO) is an enzyme that is present in the granules of myeloid cells, including myeloblasts. The presence of myeloperoxidase in the blasts is a strong indicator that the leukemia is of myeloid origin, as it is expressed by cells of the myeloid lineage (e.g., granulocytes, monocytes). Therefore, the expression of myeloperoxidase is highly specific for myeloid lineage and is used as a key diagnostic marker for distinguishing myeloid leukemias from other types of leukemia. Explanation of Other Options: A. Expression of CD13 by the blasts: CD13 is a myeloid-associated antigen and is found on the surface of many myeloid cells, including monocytes and granulocytes. While it is a helpful marker for identifying myeloid cells, CD13 expression is not as specific or diagnostic for establishing myeloid lineage in acute leukemia as myeloperoxidase is. It can be expressed in other hematopoietic cell types as well. B. Expression of CD33 by the blasts: CD33 is another myeloid-associated marker expressed on myeloid cells, including monocytes and granulocytes. However, like CD13, it is not as definitive for establishing myeloid lineage in acute leukemia. It is useful but less specific than myeloperoxidase for this purpose. D. Expression of cytoplasmic CD3 by the blasts: CD3 is a marker for T cells, not myeloid cells. Cytoplasmic CD3 expression on blasts would suggest a T-cell origin of leukemia, which is inconsistent with myeloid lineage.",
      "correct_choice_id": 221769,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75721501700646538/75721501700646538.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75721501700646538/75721501700646538.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51406,
      "choices": [
        {
          "id": 221771,
          "text": "T(8;21)(q22;q22); RUNX1-RUNX1T1"
        },
        {
          "id": 221772,
          "text": "Normal karyotype"
        },
        {
          "id": 221773,
          "text": "Complex karyotype"
        },
        {
          "id": 221774,
          "text": "T(15;17)(q22;q12); PML-RARA"
        }
      ],
      "text": "Which of the following molecular genetic abnormalities would be most likely to impart a poor prognosis in a patient with acute myeloid leukemia?",
      "unique_key": "Q8003304",
      "question_audio": null,
      "question_video": null,
      "map_id": 34950272,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Complex karyotype A complex karyotype refers to a chromosomal abnormality in which there are multiple structural and numerical chromosomal changes, typically involving three or more distinct abnormalities. In acute myeloid leukemia (AML), the presence of a complex karyotype is a poor prognostic indicator. It is associated with worse overall survival and lower response rates to treatment. Patients with complex karyotypes have a more aggressive form of the disease and are less likely to achieve durable remission. Explanation of Other Options: A. T(8;21)(q22;q22); RUNX1-RUNX1T1: This is a recurrent genetic abnormality seen in a subset of AML patients, specifically those with the AML1-ETO fusion gene. This translocation is generally associated with favorable prognosis and is often treatable with chemotherapy, leading to a better outcome compared to patients with more complex karyotypes. B. Normal karyotype: A normal karyotype in AML patients refers to the absence of detectable chromosomal abnormalities. This is generally considered intermediate in terms of prognosis. However, certain molecular mutations (e.g., NPM1 mutations, FLT3-ITD) can provide more specific prognostic information, which might affect treatment outcomes. While a normal karyotype is not inherently poor, it does not automatically guarantee a favorable outcome without further molecular testing. D. T(15;17)(q22;q12); PML-RARA: This translocation is characteristic of acute promyelocytic leukemia (APL), a subtype of AML. APL with t(15;17) is actually associated with a favorable prognosis because it is highly responsive to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Patients with this translocation have an excellent overall survival and remission rate.",
      "correct_choice_id": 221773,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48139081700646552/48139081700646552.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48139081700646552/48139081700646552.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51407,
      "choices": [
        {
          "id": 221775,
          "text": "CD13"
        },
        {
          "id": 221776,
          "text": "CD33"
        },
        {
          "id": 221777,
          "text": "MPO"
        },
        {
          "id": 221778,
          "text": "HLA-DR"
        }
      ],
      "text": "Which of the following antigens is not typically expressed in acute promyelocytic leukemia with PML-RARA?",
      "unique_key": "Q6540065",
      "question_audio": null,
      "question_video": null,
      "map_id": 34630907,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) HLA-DR HLA-DR is not typically expressed in acute promyelocytic leukemia (APL) with the PML-RARA fusion gene. APL is a subtype of acute myeloid leukemia (AML) that is characterized by the presence of the t(15;17) translocation, which results in the PML-RARA fusion gene. This fusion gene causes a block in differentiation of the promyelocytes, leading to the accumulation of immature myeloid cells. The most notable immunophenotypic features of APL are the absence or low expression of certain markers like HLA-DR, which are typically found on immature myeloid cells. The PML-RARA fusion gene has a strong association with reduced expression of HLA-DR. Explanation of Other Options: A. CD13: CD13 is a myeloid marker and is commonly expressed in acute promyelocytic leukemia (APL). It is found on the surface of granulocytes and monocytes and is typically present on the blast cells in AML, including in APL. B. CD33: CD33 is another myeloid marker commonly expressed in acute promyelocytic leukemia (APL). Like CD13, it is found on the surface of myeloid cells, and its presence is a characteristic feature of AML in general, including APL. C. MPO (Myeloperoxidase): MPO is an enzyme found in the granules of myeloid cells, and its expression is a key feature of acute promyelocytic leukemia (APL). MPO positivity is often used to confirm myeloid lineage in AML, including APL.",
      "correct_choice_id": 221778,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21566821700646566/21566821700646566.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21566821700646566/21566821700646566.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51408,
      "choices": [
        {
          "id": 221779,
          "text": "15q22"
        },
        {
          "id": 221780,
          "text": "17q21"
        },
        {
          "id": 221781,
          "text": "18q11.2"
        },
        {
          "id": 221782,
          "text": "11q13"
        }
      ],
      "text": "On which chromosome is the retinoic acid receptor α gene located?",
      "unique_key": "Q1045653",
      "question_audio": null,
      "question_video": null,
      "map_id": 34784774,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) 17q21 The retinoic acid receptor alpha (RAR-?) gene, which is involved in acute promyelocytic leukemia (APL) through the PML-RARA fusion gene, is located on chromosome 17q21. The fusion of the PML gene on chromosome 15 with the RAR-? gene on chromosome 17 results in the t(15;17) translocation, which is characteristic of APL. This translocation causes the PML-RARA fusion protein, which impairs normal differentiation of promyelocytes and contributes to the pathogenesis of APL. Explanation of Other Options: A. 15q22: The PML gene, which is involved in the t(15;17) translocation, is located on chromosome 15 at the q22 region, but this is the location of the PML gene, not the RAR-? gene. C. 18q11.2: This is not the location of either the PML or RAR-? genes. There is no significant association of this chromosomal region with APL or the retinoic acid receptor gene. D. 11q13: This region is associated with other oncogenes in different cancers, but not with the retinoic acid receptor alpha (RAR-?) gene, which is located on chromosome 17q21",
      "correct_choice_id": 221780,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44433621700646580/44433621700646580.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44433621700646580/44433621700646580.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51409,
      "choices": [
        {
          "id": 221783,
          "text": "Percentage of blasts in the peripheral blood"
        },
        {
          "id": 221784,
          "text": "Immunophenotype of the leukemic blasts"
        },
        {
          "id": 221785,
          "text": "Percentage of blasts in the bone marrow"
        },
        {
          "id": 221786,
          "text": "Karyotype of the leukemic blasts"
        }
      ],
      "text": "Which of the following is the strongest predictor of response to therapy in acute myeloid leukemia?",
      "unique_key": "Q8308244",
      "question_audio": null,
      "question_video": null,
      "map_id": 34206181,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Karyotype of the leukemic blasts The karyotype of the leukemic blasts is the strongest predictor of response to therapy in acute myeloid leukemia (AML). The genetic abnormalities or chromosomal changes that occur in AML can significantly affect the prognosis and response to treatment. Cytogenetic abnormalities such as t(8;21), inv(16), and t(15;17) (associated with acute promyelocytic leukemia) are generally associated with a better prognosis and may respond well to specific treatments such as retinoid therapy. Conversely, complex karyotype (more than 3 chromosomal abnormalities) and certain other genetic changes (e.g., monosomy 7) are associated with poor prognosis and a reduced response to therapy. Thus, the karyotype provides crucial information that can guide treatment decisions, including the choice of chemotherapy and stem cell transplantation. Explanation of Other Options: A. Percentage of blasts in the peripheral blood: The percentage of blasts in the peripheral blood is often used to monitor disease progression or response to therapy, but it is not as strong a predictor of response as the karyotype. Peripheral blood blast count can fluctuate, and its significance depends on other factors. B. Immunophenotype of the leukemic blasts: Immunophenotyping is helpful in determining the lineage of the leukemia (myeloid vs. lymphoid) and in detecting specific markers, but it does not directly correlate with the likelihood of response to therapy. However, certain markers (e.g., CD33 or CD13) can be targeted therapeutically in some cases. C. Percentage of blasts in the bone marrow: The percentage of blasts in the bone marrow can provide important information about disease burden and remission status. However, the karyotype is a more decisive factor in determining prognosis and predicting response to therapy, as it reflects underlying genetic abnormalities that influence the behavior of the leukemia.",
      "correct_choice_id": 221786,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35656301700646594/35656301700646594.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35656301700646594/35656301700646594.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51410,
      "choices": [
        {
          "id": 221787,
          "text": "Myelodysplastic syndrome"
        },
        {
          "id": 221788,
          "text": "Chronic myeloid leukemia, BCR-ABL1+"
        },
        {
          "id": 221789,
          "text": "Chronic lymphocytic leukemia"
        },
        {
          "id": 221790,
          "text": "acute moieloid leukemi"
        }
      ],
      "text": "All of the following are causes of increased blasts in the bone marrow except:",
      "unique_key": "Q6950043",
      "question_audio": null,
      "question_video": null,
      "map_id": 34097873,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) BLASTS ARE IMMATURE CELLS SEEN IN PERIPHERAL BLOOD WHENEVER THEIR PRODUCTION IS INCREASED DUE TO EITHER A MALIGNANT PROCESS LIKE IN OPTIONS A AND B OR WHEN THE MARROW IS PRODUCING CELLS AT A VERY HIGH RATE THUS NOT ALLOWING TIME TO THE IMMATURE CELLS TO MATURE, WHICH RELEASES THEM INTO CIRCULATION (REFERRED TO AS LEFT SHIFT) AS SEEN IN OPTION D. OPTION C IS A MALIGNANCY OF MATURE LYMPHOCYTES AND DOES NOT CONTAIN BLASTS.",
      "correct_choice_id": 221789,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75014891700646610/75014891700646610.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75014891700646610/75014891700646610.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51411,
      "choices": [
        {
          "id": 221791,
          "text": "Being six years of age"
        },
        {
          "id": 221792,
          "text": "Presence of t(12;21) (p13.2;q22.1);ETV6-RNX1"
        },
        {
          "id": 221793,
          "text": "Presence of MLL (KMT2A) gene rearrangement"
        },
        {
          "id": 221794,
          "text": "Lack of central nervous system involvement at presentation"
        }
      ],
      "text": "Which of the following is an unfavourable factor for a child with B-lymphoblastic leukemia/ lymphoma?",
      "unique_key": "Q2012093",
      "question_audio": null,
      "question_video": null,
      "map_id": 34499246,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Presence of MLL (KMT2A) gene rearrangement The presence of MLL (KMT2A) gene rearrangement is a unfavorable factor in childhood B-lymphoblastic leukemia/lymphoma (B-ALL). The MLL gene is located on chromosome 11q23, and its rearrangement is associated with a poor prognosis in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This gene rearrangement typically results in an aggressive disease course, resistance to standard chemotherapy, and a higher risk of relapse. Children with MLL gene rearrangement tend to have poorer overall survival rates, and they may require more intensive or experimental treatment options, including stem cell transplantation or targeted therapies. Incorrect Options: A. Being six years of age: The age of six years is not considered a significant unfavorable factor in childhood B-ALL. In fact, age between 2 and 5 years is typically associated with a better prognosis. Younger children (under age 1) and older children (over age 10) may have a worse prognosis, but age 6 is considered to fall in the intermediate-risk group for prognosis in B-ALL. B. Presence of t(12;21)(p13.2;q22.1); ETV6-RUNX1: The t(12;21) translocation involving the ETV6-RUNX1 fusion gene is actually considered a favorable factor in childhood B-ALL. This genetic abnormality is one of the most common chromosomal alterations in pediatric B-ALL and is associated with a good prognosis and excellent response to treatment. This translocation is often detected in children who achieve long-term remission with standard chemotherapy regimens. D. Lack of central nervous system involvement at presentation: Lack of central nervous system (CNS) involvement at presentation is a favorable factor in childhood B-ALL. CNS involvement at the time of diagnosis is associated with a poorer prognosis, and the presence of leukemia cells in the CNS often requires additional treatment, such as intrathecal chemotherapy, to prevent relapse. The absence of CNS involvement is an indicator that the disease is less widespread and may respond better to therapy.",
      "correct_choice_id": 221793,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28248521700646622/28248521700646622.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28248521700646622/28248521700646622.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51412,
      "choices": [
        {
          "id": 221795,
          "text": "CD19"
        },
        {
          "id": 221796,
          "text": "CD10"
        },
        {
          "id": 221797,
          "text": "TdT"
        },
        {
          "id": 221798,
          "text": "None of the above"
        }
      ],
      "text": "Which of the following antigens is specific for B-lymphoblastic leuke mia/ lymphoma by flow cytometry?",
      "unique_key": "Q8008949",
      "question_audio": null,
      "question_video": null,
      "map_id": 34690142,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) CD19 Explanation: CD19 is a cell surface antigen that is specifically expressed on B lymphocytes at various stages of development, including B-lymphoblastic leukemia/lymphoma (B-ALL). It is one of the most reliable markers for identifying B cell lineage in flow cytometry. In B-ALL, CD19 is almost universally expressed on the leukemic blasts, making it a specific marker for B-cell malignancies. This antigen is used extensively in diagnostic flow cytometry to confirm B-cell lineage and is crucial for diagnosing B-ALL or B-lymphoblastic lymphoma. Incorrect Options: B. CD10: CD10 is a cell surface antigen that is commonly expressed in early pre-B cells and in some B-ALL cases. However, CD10 is not specific to B-ALL because it can also be found on T cells, follicular dendritic cells, and in certain non-hematopoietic cells. Therefore, while CD10 is useful in differentiating B-ALL from other leukemias, it is not as specific as CD19. C. TdT: TdT (Terminal deoxynucleotidyl transferase) is an enzyme that is expressed during the early stages of B-cell and T-cell development, including B-ALL. While it is expressed in most B-ALL cases, TdT is not specific for B-ALL because it is also expressed in T-lymphoblastic leukemia/lymphoma (T-ALL). Therefore, although TdT can be a helpful marker for identifying immature lymphoid cells, it does not uniquely identify B-ALL. D. None of the above: Since CD19 is specific for B-ALL, this option is incorrect. CD19 is a defining marker for B-lymphoblastic leukemia/lymphoma by flow cytometry.",
      "correct_choice_id": 221795,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55604361700646638/55604361700646638.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55604361700646638/55604361700646638.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51413,
      "choices": [
        {
          "id": 221799,
          "text": ">15% ring sideroblasts (as a percentage of all erythroid cells) in the bone marrow"
        },
        {
          "id": 221800,
          "text": "Anemia"
        },
        {
          "id": 221801,
          "text": "2% blasts with Auer rods in the peripheral blood"
        },
        {
          "id": 221802,
          "text": "Presence of SF3B1 mutation"
        }
      ],
      "text": "Which of the following is not a feature of myelodysplastic syndrome with ringed sideroblasts?",
      "unique_key": "Q4184674",
      "question_audio": null,
      "question_video": null,
      "map_id": 34128687,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) 2% blasts with Auer rods in the peripheral blood Explanation: Option C is the correct answer because the presence of Auer rods in the peripheral blood is not a feature of myelodysplastic syndrome with ringed sideroblasts (MDS-RS). Auer rods are characteristic of acute myeloid leukemia (AML), particularly in the myeloblasts, and their presence in peripheral blood would suggest an acute leukemia rather than myelodysplastic syndrome. MDS-RS is typically associated with cytopenias, dysplastic changes, and ringed sideroblasts, but not with Auer rods. Incorrect Answers: A. >15% ring sideroblasts (as a percentage of all erythroid cells) in the bone marrow: This is a key diagnostic feature of MDS with ringed sideroblasts. Ringed sideroblasts are erythroid precursor cells that contain iron-laden mitochondria arranged in a ring around the nucleus. In MDS-RS, the percentage of ringed sideroblasts in the bone marrow should be greater than 15%, which is a defining characteristic. B. Anemia: Anemia is a common finding in MDS, including MDS with ringed sideroblasts. This occurs due to ineffective erythropoiesis, where the production of mature red blood cells is impaired. Anemia is typically seen in the majority of MDS cases, and is often one of the presenting symptoms. D. Presence of SF3B1 mutation: The SF3B1 mutation is a common genetic mutation found in MDS with ringed sideroblasts. It is associated with MDS-RS and is an important diagnostic and prognostic marker. This mutation affects splicing factors and contributes to the pathophysiology of the disease.",
      "correct_choice_id": 221801,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2483091700646652/2483091700646652.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2483091700646652/2483091700646652.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51414,
      "choices": [
        {
          "id": 221803,
          "text": "The fusion protein p210 is most frequently seen in chronic myeloid leukemia, BCR-ABL1 positive"
        },
        {
          "id": 221804,
          "text": "The fusion protein p190 is most frequently seen in Philadelphia chromosome-positive B-lymphoblastic leukemia/lymphoma"
        },
        {
          "id": 221805,
          "text": "The fusion protein p230 is associated with morphologic features that resemble chronic myelomonocytic leukemia"
        },
        {
          "id": 221806,
          "text": "The fusion protein p230 is associated with increased neutrophilic maturation in chronic myeloid leukemia"
        }
      ],
      "text": "Which of the following statements regarding t(9;22)(q34;q11.2); BCR-ABL1 and its resultant fusion proteins is false?",
      "unique_key": "Q2415577",
      "question_audio": null,
      "question_video": null,
      "map_id": 34500542,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) The fusion protein p230 is associated with morphologic features that resemble chronic myelomonocytic leukemia Option C is the correct answer because the fusion protein p230 does not cause features resembling chronic myelomonocytic leukemia (CMML). The p230 fusion protein is typically associated with a variant form of chronic myeloid leukemia (CML), known as \"CML with p230 fusion protein\". This variant can cause neutrophil maturation defects but is not specifically linked with CMML, which is a distinct type of leukemia characterized by a mixture of features between CML and acute myeloid leukemia (AML). Incorrect Answers: A. The fusion protein p210 is most frequently seen in chronic myeloid leukemia, BCR-ABL1 positive: This is true. The p210 fusion protein is the most common form resulting from the t(9;22)(q34;q11.2) translocation in chronic myeloid leukemia (CML). This fusion protein arises from the BCR-ABL1 fusion gene and is typically seen in patients with CML. B. The fusion protein p190 is most frequently seen in Philadelphia chromosome-positive B-lymphoblastic leukemia/lymphoma: This is true. The p190 fusion protein is commonly seen in Philadelphia chromosome-positive B-lymphoblastic leukemia/lymphoma (B-ALL). This smaller fusion protein results from the BCR-ABL1 translocation, which has a different functional impact compared to the larger p210 protein seen in CML. D. The fusion protein p230 is associated with increased neutrophilic maturation in chronic myeloid leukemia: This is true. The p230 fusion protein is associated with increased neutrophilic maturation in CML. It is typically seen in a subtype of CML and can lead to relatively milder disease with a better prognosis than the typical p210-positive CML.",
      "correct_choice_id": 221805,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21991951700646664/21991951700646664.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21991951700646664/21991951700646664.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51415,
      "choices": [
        {
          "id": 221807,
          "text": "CD1a"
        },
        {
          "id": 221808,
          "text": "Cytoplasmic CD22"
        },
        {
          "id": 221809,
          "text": "Cytoplasmic CD3"
        },
        {
          "id": 221810,
          "text": "Surface CD4"
        }
      ],
      "text": "Detection of which of the following antigens by flow cytometry is diagnostic of T-cell differentiation in acute lymphoblastic leukemia?",
      "unique_key": "Q6148104",
      "question_audio": null,
      "question_video": null,
      "map_id": 34762720,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Cytoplasmic CD3 The presence of cytoplasmic CD3 is diagnostic of T-cell differentiation in acute lymphoblastic leukemia (ALL). CD3 is a key T-cell marker that is expressed on all T cells, but when it is detected in the cytoplasmic form, it indicates T-cell lineage in lymphoid neoplasms. It is a critical marker used to confirm the T-cell origin of lymphoblasts in T-ALL. Incorrect Answers: A. CD1a: CD1a is a marker that is typically expressed on a subset of immature T cells, especially those in the thymus. While it can be used to detect early T-cell differentiation, it is not as definitive as cytoplasmic CD3 for confirming T-cell differentiation in ALL. B. Cytoplasmic CD22: CD22 is a marker specific to B cells, particularly expressed on the surface of B lymphocytes and is used to diagnose B-ALL, not T-ALL. Cytoplasmic CD22 would not be diagnostic for T-cell differentiation. D. Surface CD4: CD4 is a T-cell co-receptor expressed on helper T cells, but its presence alone is insufficient to diagnose T-cell differentiation in T-ALL. Cytoplasmic CD3 is the more definitive marker for T-cell differentiation in ALL.",
      "correct_choice_id": 221809,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14266661700646722/14266661700646722.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14266661700646722/14266661700646722.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51416,
      "choices": [
        {
          "id": 221811,
          "text": "The disease involves the red pulp of the spleen"
        },
        {
          "id": 221812,
          "text": "There is leucocytosis"
        },
        {
          "id": 221813,
          "text": "Monocytopenia occurs"
        },
        {
          "id": 221814,
          "text": "Bone marrow aspiration may result in a dry tap"
        }
      ],
      "text": "All of the following are features of hairy cell leukemia except:",
      "unique_key": "Q5005256",
      "question_audio": null,
      "question_video": null,
      "map_id": 34076585,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) There is leucocytosis Hairy cell leukemia (HCL) is a rare form of leukemia characterized by specific clinical and laboratory findings. One of the typical features of HCL is leucopenia (a decrease in white blood cell count), not leucocytosis. Most patients with HCL present with pancytopenia, which includes low white blood cells, red blood cells, and platelets. Therefore, B is the correct answer because leucocytosis (increased white blood cells) is not a characteristic of HCL. Incorrect Responses: A. The disease involves the red pulp of the spleen: HCL typically involves splenic red pulp and is often associated with splenomegaly. The red pulp is the part of the spleen that is responsible for filtering blood and removing abnormal cells. In HCL, the red pulp becomes infiltrated with hairy cells, contributing to splenomegaly. Thus, this is a feature of HCL, making A incorrect. C. Monocytopenia occurs: Monocytopenia (low monocyte count) is a well-known feature of HCL. Hairy cells are abnormal B lymphocytes that infiltrate various organs, including the bone marrow, where they suppress the production of other blood cells. This results in monocytopenia, which is a characteristic feature of HCL. Therefore, C is correct. D. Bone marrow aspiration may result in a dry tap: A dry tap occurs when a bone marrow aspiration does not yield any material due to fibrosis or infiltration by abnormal cells. In HCL, the bone marrow is often infiltrated by hairy cells, which can lead to marrow fibrosis, making it difficult to obtain a sample through aspiration. This is a typical finding in HCL, so D is correct.",
      "correct_choice_id": 221812,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20515601700646970/20515601700646970.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20515601700646970/20515601700646970.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51417,
      "choices": [
        {
          "id": 221815,
          "text": "Annexin 1"
        },
        {
          "id": 221816,
          "text": "CD25"
        },
        {
          "id": 221817,
          "text": "CD103"
        },
        {
          "id": 221818,
          "text": "CD3"
        }
      ],
      "text": "All of the following markers are expected to be positive in hairy cell leukemia except:",
      "unique_key": "Q8902927",
      "question_audio": null,
      "question_video": null,
      "map_id": 34514317,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) CD3 Hairy cell leukemia (HCL) is a B-cell malignancy characterized by the presence of hairy cells, which express a specific panel of markers. CD3 is a T-cell marker, and its expression is not expected in HCL, as the disease originates from B cells. Therefore, D is the correct answer because CD3 is not typically expressed in hairy cell leukemia. Incorrect Responses: A. Annexin 1: Annexin 1 is a protein marker expressed in hairy cell leukemia. It is part of the characteristic immunophenotype seen in HCL and helps distinguish it from other B-cell malignancies. Thus, A is incorrect. B. CD25: CD25, the IL-2 receptor alpha chain, is a hallmark marker of HCL. It is typically expressed on hairy cells, making it a positive marker in this condition. CD25 is commonly used in the immunophenotypic diagnosis of HCL. Therefore, B is incorrect. C. CD103: CD103, an integrin marker, is another positive marker commonly seen in hairy cell leukemia. Its presence helps to further define HCL and differentiate it from other B-cell malignancies. CD103 is often used in combination with other markers to confirm the diagnosis of HCL. Thus, C is incorrect.",
      "correct_choice_id": 221818,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62548721700646983/62548721700646983.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62548721700646983/62548721700646983.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51418,
      "choices": [
        {
          "id": 221819,
          "text": "T-cell prolymphocytic leukemia"
        },
        {
          "id": 221820,
          "text": "T-cell large granularlymphocyticleukemia"
        },
        {
          "id": 221821,
          "text": "Adult T-cell leukemia/lymphoma"
        },
        {
          "id": 221822,
          "text": "Aggressive NK-cell leukemia"
        }
      ],
      "text": "A 55-years-old Caucasian woman presents for evaluation of fatigue. The patient states that her symptoms have been present for approximately eight months and reports two episodes of cellulitis over the last year. Physical examination reveals mild splenomegaly; no skin lesion, lymphadenopathy, or other abnormalities are identified. Review of a complete blood count (CBC) and peripheral blood smear shows absolute neutropenia, normocytic, normochromic anemia, and mild absolute lymphocytosis composed of numerous large lymphocytes with abundant cytoplasm and prominent red-pink granules. Which of the following is the most likely diagnosis?",
      "unique_key": "Q8317095",
      "question_audio": null,
      "question_video": null,
      "map_id": 34231409,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Presence of granules suggests LGL T-cell large granular lymphocytic leukaemia (t-lgll) is a heterogeneous disorder characterized by a persistent (> 6 months) increase in the number of peripheral blood large granular lymphocytes (lgls), usually to 2- 20 x 109/l, without a clearly identified cause. T-lgll involves the peripheral blood, bone marrow, liver, spleen, and rarely skin. Lymphadenopathy is very rare. Most cases have an indolent clinical course. Severe neutropenia (with or without anaemia) is frequent. Moderate splenomegaly is the main physical finding. Rheumatoid arthritis, the presence of autoantibodies, circulating immune complexes, and hypergammaglobulinaemia are also common. The predominant lymphocytes in blood and bone marrow films are lgls with moderate to abundant cytoplasm and fine or course azurophilic granules. The granules are positive for acid phosphatase and beta-glucuronidase.",
      "correct_choice_id": 221820,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20367921700647023/20367921700647023.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20367921700647023/20367921700647023.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51419,
      "choices": [
        {
          "id": 221823,
          "text": "Female sex"
        },
        {
          "id": 221824,
          "text": "Leukocyte count < 50,000"
        },
        {
          "id": 221825,
          "text": "Age greater than 1 year"
        },
        {
          "id": 221826,
          "text": "Hypodiploidy"
        }
      ],
      "text": "Poor prognostic indicator of All is",
      "unique_key": "Q7588019",
      "question_audio": null,
      "question_video": null,
      "map_id": 34628286,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hypodiploidy Explanation: Hypodiploidy, which refers to a lower than normal chromosome number (less than 46 chromosomes), is a poor prognostic indicator in acute lymphoblastic leukemia (ALL). It is associated with a worse prognosis due to the presence of more aggressive leukemic cells and a tendency to relapse despite treatment. This genetic abnormality often reflects complex chromosomal abnormalities, which make treatment resistance more likely. Hypodiploidy is generally considered a high-risk factor in ALL and is predictive of poorer treatment outcomes and survival. Incorrect Responses: A. Female sex: While gender can influence the overall incidence of ALL, with males generally having a higher incidence, female sex is not a poor prognostic factor. In fact, females often have a better prognosis than males when diagnosed with ALL. Thus, female sex is not typically associated with a poor prognosis in ALL. B. Leukocyte count < 50,000: A low leukocyte count (< 50,000/µL) is typically a good prognostic indicator in ALL. Higher leukocyte counts are usually associated with more advanced disease and a higher risk of central nervous system involvement, which negatively affects prognosis. Therefore, a low leukocyte count generally suggests less aggressive disease and is not a poor prognostic factor. C. Age greater than 1 year: Age greater than 1 year is a moderate risk factor in ALL, but it is not the worst. Infants (under 1 year) and older adults are considered to have poorer prognoses, with the latter often being associated with treatment resistance and higher rates of relapse. However, age greater than 1 year by itself is not as poor a prognostic indicator as hypodiploidy.",
      "correct_choice_id": 221826,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4716671700647231/4716671700647231.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4716671700647231/4716671700647231.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51420,
      "choices": [
        {
          "id": 221827,
          "text": "T cells"
        },
        {
          "id": 221828,
          "text": "Immature B cells"
        },
        {
          "id": 221829,
          "text": "Immature T cells"
        },
        {
          "id": 221830,
          "text": "Both T and B cells"
        }
      ],
      "text": "B ALL is due to",
      "unique_key": "Q3181300",
      "question_audio": null,
      "question_video": null,
      "map_id": 34780193,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Immature B cells B-cell Acute Lymphoblastic Leukemia (B-ALL) is a type of leukemia that arises from immature B cells. B-ALL is characterized by the uncontrolled proliferation of these early-stage B lymphocytes, which have not yet fully matured into functional plasma cells or memory B cells. In B-ALL, the abnormal proliferation of these immature B cells disrupts normal blood cell production and leads to symptoms like anemia, thrombocytopenia, and neutropenia. The majority of cases of ALL (Acute Lymphoblastic Leukemia) are B-cell in origin, with B-ALL being the most common type in both children and adults. Incorrect Responses: A. T cells: T-cell ALL (T-ALL) is a distinct type of ALL that arises from immature T cells rather than B cells. While T-ALL is less common than B-ALL, it still represents a significant proportion of acute lymphoblastic leukemias. However, this is not the correct answer to this question, as the query specifically refers to B-ALL, which involves B cells, not T cells. C. Immature T cells: As mentioned in option A, immature T cells lead to T-ALL, not B-ALL. Therefore, immature T cells are not responsible for B-ALL, and this option is incorrect. D. Both T and B cells: B-ALL is specifically due to the malignancy of B cells. If both T cells and B cells were involved, this would imply a mixed lineage leukemia or a different pathology, but B-ALL is due to the expansion of immature B cells only. Thus, this option is also incorrect.",
      "correct_choice_id": 221828,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58994601700647277/58994601700647277.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58994601700647277/58994601700647277.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51421,
      "choices": [
        {
          "id": 221831,
          "text": "ALL"
        },
        {
          "id": 221832,
          "text": "CLL"
        },
        {
          "id": 221833,
          "text": "HCL"
        },
        {
          "id": 221834,
          "text": "CML"
        }
      ],
      "text": "CD10 is seen in",
      "unique_key": "Q5900478",
      "question_audio": null,
      "question_video": null,
      "map_id": 34506045,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) ALL CD10, also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), is a surface marker commonly expressed on immature B cells and is often seen in Acute Lymphoblastic Leukemia (ALL), particularly in B-cell ALL. CD10 is a cell-surface protease involved in various cellular processes, and its expression helps differentiate ALL from other types of leukemia. The presence of CD10 is a marker of immature B-cells, making it useful in diagnosing ALL, especially in distinguishing it from other lymphoid malignancies. Incorrect Responses: B. CLL: Chronic Lymphocytic Leukemia (CLL) primarily involves mature B cells. The hallmark markers of CLL are CD5, CD19, and CD23, but CD10 is typically absent or present at very low levels in CLL. Thus, CD10 is not a diagnostic marker for CLL, making this option incorrect. C. HCL: Hairy Cell Leukemia (HCL) is a rare type of leukemia that involves mature B cells and typically expresses CD11c, CD25, CD103, and CD123. CD10 is usually negative in HCL. Therefore, CD10 is not characteristic of HCL, making this option incorrect. D. CML: Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder, not a lymphoproliferative one. It is characterized by the presence of the Philadelphia chromosome (t(9;22)) and typically involves myeloid cells. CD10 is not a marker for CML, as this disorder does not involve the B-lymphocyte lineage, making this option incorrect.",
      "correct_choice_id": 221831,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51237341700647288/51237341700647288.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51237341700647288/51237341700647288.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51422,
      "choices": [
        {
          "id": 221835,
          "text": "Hyperdiploidy"
        },
        {
          "id": 221836,
          "text": "Hypodiploidy"
        },
        {
          "id": 221837,
          "text": "T cell lineage"
        },
        {
          "id": 221838,
          "text": "Philadelphia chromosome"
        }
      ],
      "text": "Good prognosis of ALL",
      "unique_key": "Q8682468",
      "question_audio": null,
      "question_video": null,
      "map_id": 34025355,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hyperdiploidy Hyperdiploidy, which refers to the presence of more than the normal number of chromosomes (specifically, 51-67 chromosomes) in the leukemic cells, is associated with a good prognosis in Acute Lymphoblastic Leukemia (ALL), particularly in children. The presence of hyperdiploidy is linked to better chemotherapy response, a higher rate of remission, and a more favorable overall survival rate. It is one of the favorable cytogenetic markers in ALL, suggesting a higher likelihood of treatment success. Incorrect Responses: B. Hypodiploidy: Hypodiploidy, which refers to the presence of fewer than the normal number of chromosomes (usually less than 44), is associated with poor prognosis in ALL. It is linked to a more aggressive disease course and a lower response to therapy. Therefore, this option is incorrect as it suggests a poor rather than good prognosis. C. T cell lineage: T-cell lineage in ALL generally indicates a more aggressive disease with a poorer prognosis compared to B-cell lineage. While T-cell ALL is treatable, it often presents with a more challenging clinical course and worse outcomes, especially if associated with higher white blood cell counts and unfavorable genetic features. Hence, this option is incorrect. D. Philadelphia chromosome: The Philadelphia chromosome (t(9;22)) is a cytogenetic abnormality most commonly seen in Chronic Myelogenous Leukemia (CML) but can also be present in ALL (specifically in adult B-cell ALL). The presence of the Philadelphia chromosome in ALL is associated with a poor prognosis due to the production of the BCR-ABL fusion protein, which drives leukemogenesis and contributes to resistance to standard chemotherapy. Therefore, this option is incorrect as it suggests a poor prognosis.",
      "correct_choice_id": 221835,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74227821700647302/74227821700647302.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74227821700647302/74227821700647302.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51423,
      "choices": [
        {
          "id": 221839,
          "text": "Age of onset between 2-8 years"
        },
        {
          "id": 221840,
          "text": "Initial WBC count less than 50000"
        },
        {
          "id": 221841,
          "text": "Hyperdiploidy"
        },
        {
          "id": 221842,
          "text": "t (9:22), t (8:14), t (4:11)"
        }
      ],
      "text": "All of the following are good prognostic factors for ALL except",
      "unique_key": "Q9451748",
      "question_audio": null,
      "question_video": null,
      "map_id": 34033834,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) t(9:22), t(8:14), t(4:11) The cytogenetic abnormalities t(9;22) (Philadelphia chromosome), t(8;14), and t(4;11) are all associated with poor prognostic factors in Acute Lymphoblastic Leukemia (ALL). These translocations, which involve key oncogenes, contribute to disease resistance to treatment and a higher likelihood of relapse. The Philadelphia chromosome in particular is linked with the production of the BCR-ABL fusion protein, which imparts a poor prognosis and resistance to conventional chemotherapy. Therefore, t(9;22), t(8;14), and t(4:11) are not good prognostic factors, making option D the correct answer. Incorrect Responses: A. Age of onset between 2-8 years: Age between 2-8 years is associated with a good prognosis in ALL, especially in children. This age group has the highest cure rates due to better chemotherapy tolerance and response, as well as more favorable genetic features. This makes option A a correct, favorable prognostic factor for ALL. B. Initial WBC count less than 50000: An initial WBC count less than 50,000 at diagnosis is a favorable prognostic factor in ALL. Lower WBC counts at diagnosis typically indicate less aggressive disease and a better response to treatment. Therefore, option B is a favorable prognostic factor. C. Hyperdiploidy: As mentioned in the previous question, hyperdiploidy (the presence of extra chromosomes) is associated with a better prognosis in ALL, particularly in children. It is linked to higher remission rates and better overall survival. Therefore, this is a favorable prognostic factor, making option C correct.",
      "correct_choice_id": 221842,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20001101700647313/20001101700647313.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20001101700647313/20001101700647313.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51424,
      "choices": [
        {
          "id": 221843,
          "text": "Megakaryocytic leukemia"
        },
        {
          "id": 221844,
          "text": "Lymphocytic leukemia"
        },
        {
          "id": 221845,
          "text": "Erythroleukemia"
        },
        {
          "id": 221846,
          "text": "AML M4 and M5"
        }
      ],
      "text": "Nonspecific esterase in present in",
      "unique_key": "Q3975187",
      "question_audio": null,
      "question_video": null,
      "map_id": 34239850,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) AML M4 and M5 Nonspecific esterase (NSE) is an enzyme typically present in the cytoplasm of certain types of leukemia cells, particularly in acute myeloid leukemia (AML) subtypes M4 and M5. These subtypes are characterized by the presence of monocytes or monocytic differentiation, and nonspecific esterase is a key marker of monocytic lineage. The enzyme is involved in the hydrolysis of ester bonds and is a diagnostic tool to identify monoblasts and promonocytes, which are prevalent in AML M4 (monocytic) and AML M5 (monoblastic). Therefore, option D is the correct answer. Incorrect Responses: A. Megakaryocytic leukemia: Megakaryocytic leukemia, a rare subtype of AML characterized by the proliferation of megakaryocytes, typically does not express nonspecific esterase. Instead, megakaryocytic markers such as CD41, CD61, and platelet glycoproteins are more specific. Hence, nonspecific esterase is not associated with this leukemia subtype. B. Lymphocytic leukemia: Lymphocytic leukemia, including both acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), does not express nonspecific esterase. Lymphocytic leukemias are typically positive for CD19, CD20, and other B or T cell markers but not for nonspecific esterase, which is specific to monocytic cells. C. Erythroleukemia: Erythroleukemia, an uncommon form of AML involving abnormal erythroid precursor cells, also does not exhibit positive nonspecific esterase staining. Instead, it is typically positive for glycophorin A and other markers specific to erythroid lineage, not for nonspecific esterase.",
      "correct_choice_id": 221846,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67059421700647327/67059421700647327.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67059421700647327/67059421700647327.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51425,
      "choices": [
        {
          "id": 221847,
          "text": "T (18,21)"
        },
        {
          "id": 221848,
          "text": "T (15,17)"
        },
        {
          "id": 221849,
          "text": "T (8,21)"
        },
        {
          "id": 221850,
          "text": "T (9,11)"
        }
      ],
      "text": "What is the chromosomal translocation in AML M3?",
      "unique_key": "Q6224296",
      "question_audio": null,
      "question_video": null,
      "map_id": 34179759,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) T(15,17) AML M3, also known as acute promyelocytic leukemia (APML), is specifically associated with the chromosomal translocation t(15;17). This translocation results in the fusion of the PML gene (located on chromosome 15) and the RAR? gene (located on chromosome 17), leading to the formation of the PML-RAR? fusion protein. This fusion protein disrupts normal myeloid differentiation and leads to the accumulation of abnormal promyelocytes, a hallmark of APML. This translocation is critical for both the diagnosis and treatment of APML, as it makes the disease highly responsive to all-trans retinoic acid (ATRA) therapy. Incorrect Responses: A. T(18,21): The t(18;21) translocation is associated with AML M2, not M3. It results in the fusion of the AML1 gene (located on chromosome 21) and the ETO gene (located on chromosome 18), which plays a role in the development of acute myeloblastic leukemia. This translocation is not found in acute promyelocytic leukemia (M3). C. T(8,21): The t(8;21) translocation is characteristic of AML M2 (another subtype of AML) and results in the fusion of the RUNX1 (previously called AML1) gene on chromosome 21 and the ETO gene on chromosome 8. This translocation leads to impaired myeloid differentiation, but it is not associated with AML M3. D. T(9,11): The t(9;11) translocation is typically seen in AML M5 (monoblastic leukemia) and involves the fusion of the MLL gene on chromosome 11 and the AF9 gene on chromosome 9. This translocation is characteristic of a different AML subtype, not M3.",
      "correct_choice_id": 221848,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13863421700647343/13863421700647343.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13863421700647343/13863421700647343.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51426,
      "choices": [
        {
          "id": 221851,
          "text": "Philadelphia chromosome"
        },
        {
          "id": 221852,
          "text": "Auer rods"
        },
        {
          "id": 221853,
          "text": "Hemolytic anemia"
        },
        {
          "id": 221854,
          "text": "Dohle bodies"
        }
      ],
      "text": "AML is characterized by",
      "unique_key": "Q4486841",
      "question_audio": null,
      "question_video": null,
      "map_id": 34468456,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) AML (myeloblasts) have fused granules called Auer rods and are characteristic of AML Option A can be seen in CML, AML and ALL Option D are dilated RER",
      "correct_choice_id": 221852,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38656411700647356/38656411700647356.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38656411700647356/38656411700647356.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51427,
      "choices": [
        {
          "id": 221855,
          "text": "Mycosis fungoides"
        },
        {
          "id": 221856,
          "text": "Myledysplastic syndrome"
        },
        {
          "id": 221857,
          "text": "Hairy cell leukemia"
        },
        {
          "id": 221858,
          "text": "Sezary syndrome"
        }
      ],
      "text": "A 50 years old patient comes with pancytopenia, splenomegaly and skin lesion (erythema nodosum). Most probable diagnosis is:",
      "unique_key": "Q7382595",
      "question_audio": null,
      "question_video": null,
      "map_id": 34863420,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hairy cell leukemia Hairy cell leukemia (HCL) is the most likely diagnosis in this case because it typically presents with pancytopenia (low counts of all blood cells), splenomegaly (enlargement of the spleen), and, in some cases, skin lesions like erythema nodosum. HCL is a rare B-cell lymphoproliferative disorder characterized by the presence of \"hairy\" projections on the leukemic cells seen under the microscope. The disease often results in bone marrow suppression, leading to pancytopenia, and the abnormal cells infiltrate the spleen, causing splenomegaly. Erythema nodosum is a less common but documented cutaneous manifestation, likely related to the underlying immune dysregulation. These clinical features align well with the description in the question. Why the other options are incorrect: (A) Mycosis fungoides: Mycosis fungoides is a type of cutaneous T-cell lymphoma that primarily presents with skin lesions such as patches, plaques, or tumors. While it can cause systemic symptoms in advanced stages, it is not typically associated with pancytopenia or splenomegaly. Erythema nodosum is not a typical feature of mycosis fungoides, making this diagnosis less likely. (B) Myelodysplastic syndrome (MDS): MDS is a clonal hematopoietic stem cell disorder that causes pancytopenia and ineffective blood cell production. However, MDS usually does not present with splenomegaly or specific skin manifestations like erythema nodosum. These features make MDS less likely in this patient compared to HCL. (D) Sezary syndrome: Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma characterized by erythroderma, generalized lymphadenopathy, and the presence of malignant Sezary cells in the blood. While skin lesions are a hallmark of the disease, pancytopenia and splenomegaly are not typical findings. Erythema nodosum is not a common presentation of Sezary syndrome, further ruling it out in this case.",
      "correct_choice_id": 221857,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53144801700647372/53144801700647372.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53144801700647372/53144801700647372.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51428,
      "choices": [
        {
          "id": 221859,
          "text": "CD30"
        },
        {
          "id": 221860,
          "text": "CD103"
        },
        {
          "id": 221861,
          "text": "CD1a"
        },
        {
          "id": 221862,
          "text": "CD4"
        }
      ],
      "text": "Marker for hairy cell leukemia is",
      "unique_key": "Q2747243",
      "question_audio": null,
      "question_video": null,
      "map_id": 34264046,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) CD103 CD103 is a specific marker for hairy cell leukemia (HCL). It is an integrin expressed on the surface of hairy cells and is used as a reliable diagnostic marker in flow cytometry. The co-expression of CD103 along with other markers like CD11c and CD25 is characteristic of HCL, helping distinguish it from other B-cell malignancies. The presence of CD103 is a hallmark of the disease and plays a key role in confirming the diagnosis. Why the other options are incorrect: (A) CD30: CD30 is a marker associated with Hodgkin lymphoma and certain types of non-Hodgkin lymphomas, such as anaplastic large-cell lymphoma. It is not expressed in hairy cell leukemia, making this option incorrect. (C) CD1a: CD1a is a marker typically expressed in Langerhans cells and is associated with Langerhans cell histiocytosis (LCH). It is not relevant to hairy cell leukemia and is not used as a diagnostic marker for this disease. (D) CD4: CD4 is a marker expressed on helper T-cells and is relevant in conditions like T-cell lymphomas and HIV/AIDS. It is not a marker for hairy cell leukemia, which arises from B-cells, making this option incorrect.",
      "correct_choice_id": 221860,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25109481700647394/25109481700647394.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25109481700647394/25109481700647394.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51429,
      "choices": [
        {
          "id": 221863,
          "text": "M2-AML"
        },
        {
          "id": 221864,
          "text": "M3-AML"
        },
        {
          "id": 221865,
          "text": "M6-AML"
        },
        {
          "id": 221866,
          "text": "ALL"
        }
      ],
      "text": "Auer rods are seen maximally in",
      "unique_key": "Q8806107",
      "question_audio": null,
      "question_video": null,
      "map_id": 34135391,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) M3-AML Auer rods are distinctive, rod-shaped, red-purple cytoplasmic inclusions found in myeloblasts and promyelocytes. They are composed of abnormal primary granules and are seen in acute myeloid leukemia (AML), particularly in M3-AML (acute promyelocytic leukemia, APL). Auer rods are most frequently and prominently observed in M3-AML because of the abundance of promyelocytes, which have a high granule content. Their presence is a hallmark of this subtype and is often associated with the t(15;17) translocation, which is characteristic of APL. Identifying Auer rods is important as it suggests a subtype of AML that responds well to targeted therapy with all-trans retinoic acid (ATRA). Why the other options are incorrect: (A) M2-AML (Acute myeloblastic leukemia with maturation): Auer rods can be seen in M2-AML, but they are less frequent compared to M3-AML. While M2-AML involves maturation of myeloblasts, the quantity and prominence of Auer rods are not as significant as in M3-AML, making it an incorrect answer. (C) M6-AML (Acute erythroid leukemia): M6-AML involves a predominance of erythroid precursors and often has fewer myeloblasts. Auer rods are generally not observed in this subtype because it lacks the granule-rich promyelocytes characteristic of M3-AML. (D) ALL (Acute lymphoblastic leukemia): Auer rods are never seen in ALL because this condition involves lymphoid lineage cells, which do not produce the primary granules responsible for forming Auer rods. Their presence excludes the diagnosis of ALL, making this option incorrect.",
      "correct_choice_id": 221864,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41491151700647487/41491151700647487.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41491151700647487/41491151700647487.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51430,
      "choices": [
        {
          "id": 221867,
          "text": "t(4;11)"
        },
        {
          "id": 221868,
          "text": "t(9;22)"
        },
        {
          "id": 221869,
          "text": "t(12;21)"
        },
        {
          "id": 221870,
          "text": "Hyperdiploidy"
        }
      ],
      "text": "Which of the following molecular alterations is associated with the worst clinical prognosis in patients with B-cell acute lymphoblastic leukemia?",
      "unique_key": "Q2048087",
      "question_audio": null,
      "question_video": null,
      "map_id": 34788584,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) t(9;22). The t(9;22) translocation, also known as the Philadelphia chromosome, is the most poorly prognostic molecular alteration in B-cell acute lymphoblastic leukemia (B-ALL). This translocation involves the fusion of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, creating a fusion gene that encodes for a constitutively active tyrosine kinase. This leads to uncontrolled cell proliferation and contributes to the aggressive nature of the leukemia. Patients with B-ALL harboring the Philadelphia chromosome typically have a poorer response to standard chemotherapy and worse overall survival outcomes, which is why this alteration is associated with the worst clinical prognosis. Explanation for the Incorrect Options: A. t(4;11): The t(4;11) translocation is associated with mixed lineage leukemia (MLL), which can present with both B-cell and T-cell features. This translocation often leads to a poor prognosis due to its association with high-risk features, but it is not as universally poor-prognostic as the Philadelphia chromosome (t(9;22)) in B-ALL. This translocation can occur in both acute myeloid leukemia (AML) and B-ALL, but it is still considered less detrimental in terms of prognosis when compared to t(9;22). C. t(12;21): The t(12;21) translocation, which results in the fusion of the TEL and AML1 genes, is one of the more favorable prognostic genetic alterations in B-ALL. It is associated with a better response to therapy and improved overall survival rates. Children with B-ALL harboring t(12;21) generally have a good prognosis, making this translocation associated with a more favorable outcome compared to t(9;22). D. Hyperdiploidy: Hyperdiploidy refers to an increased number of chromosomes, typically involving the gain of additional chromosomes (often in the range of 51-65 chromosomes). Hyperdiploid B-ALL is usually associated with a good prognosis, particularly in pediatric patients. This genetic alteration is less aggressive and is often seen in patients who respond well to treatment, resulting in a better clinical outcome.",
      "correct_choice_id": 221868,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33177701701074816/33177701701074816.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33177701701074816/33177701701074816.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51431,
      "choices": [
        {
          "id": 221871,
          "text": "t(8;14)"
        },
        {
          "id": 221872,
          "text": "t(9;22)"
        },
        {
          "id": 221873,
          "text": "t(11;22)"
        },
        {
          "id": 221874,
          "text": "t(14;18)"
        }
      ],
      "text": "A 46-year-old woman with prominent splenomegaly presents with a 3-month history of malaise,easy fatigability, weakness,weight loss, and anorexia. A complete blood count and differential demonstrates a white blood cell count of 250,000/mm3 with a predominance of myelocytes, metamyelocytes, band cells, and segmented neutrophils. Cytogenetic analysis is most likely to reveal which of the following translocations?",
      "unique_key": "Q1193936",
      "question_audio": null,
      "question_video": null,
      "map_id": 34504533,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) The translocation t(9;22) is the characteristic translocation associated with chronic myelogenous leukemia, forming the so-called “Philadelphia chromosome.” The resultant fusion protein,p210, has increased tyrosine kinase activity that contributes to the uncontrolled proliferation in this form of leukemia. The translocation t(14;18) is seen in follicular lymphoma; t(8;14) in Burkitt’s lymphoma; t(15;17) in the M3 variant of acute promyelocytic leukemia (AML); and t(11;22) in Ewing sarcoma, a relatively uncommon tumor of bone. College Girl Appearance on PBS<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/Pathology-6(4).jpg\" alt=\"Solution Image\"></p>",
      "correct_choice_id": 221872,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18581361701075635/18581361701075635.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18581361701075635/18581361701075635.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}